# Biofourmis Singapore Pte., Ltd.

- Location (FDA's records): Singapore, SG
- FDA decisions: 4 (2019–2024): 4 510(k) clearances
- Product codes: MSX (2), DQK (1), PLB (1)
- 510(k) review time since 2016: median 212 days, against 212 for FDA's reviews in the same codes and years (0 of 3 faster)
- Predicates its devices cite: 6 (1 its own); citations of its devices by later devices: 4 (1 its own)
- Recalls linked to its devices: 0 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms whose devices it cites most
- Current Health, Ltd.: 2 (https://510kreport.com/company/current-health)
- Cardiologs Technologies: 1 (https://510kreport.com/company/cardiologs-technologies)
- Vgbio, Inc (Dba Physiq): 1 (https://510kreport.com/company/vgbio-dba-physiq)
- Vitls, Inc.: 1 (https://510kreport.com/company/vitls)

## Firms that cite its devices most
- Medicalgorithmics S.A.: 2 (https://510kreport.com/company/medicalgorithmics)
- Spass, Inc.: 1 (https://510kreport.com/company/spass)

## Its most-cited devices
- K182344: RhythmAnalytics (2019), cited by 2
- K183282: Biovitals Analytics Engine (2019), cited by 1
- K213863: Everion+ System (2023), cited by 1

## Recent decisions
- K233418: Biofourmis Everion+ (G2) (May 9, 2024)
- K213863: Everion+ System (Feb 23, 2023)
- K183282: Biovitals Analytics Engine (Aug 15, 2019)
- K182344: RhythmAnalytics (Mar 7, 2019)

Source page: https://510kreport.com/company/biofourmis-singapore